NCT01804686 2026-04-13
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
Clinical Trials
8 trialsNCT01886872 2026-04-13
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03462719 2026-04-13
GLOW
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03701282 2026-04-13
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03737981 2026-04-13
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06136559 2026-04-13
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05254743 2026-04-01
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
NCT02477696 2026-03-27
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 3 Active not recruiting